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ARTICLE
Radionuclides transform chemotherapeutics into
phototherapeutics for precise treatment of
disseminated cancer
Nalinikanth Kotagiri 1,5, Matthew L. Cooper2, Michael Rettig2, Christopher Egbulefu1, Julie Prior1
Grace Cui2, Partha Karmakar1, Mingzhou Zhou1, Xiaoxia Yang2, Gail Sudlow1, Lynne Marsala1,
Chantiya Chanswangphuwana2, Lan Lu2, LeMoyne Habimana-Grifﬁn1, Monica Shokeen1, Xinming Xu2,
Katherine Weilbaecher2, Michael Tomasson2, Gregory Lanza2, John F. DiPersio2 & Samuel Achilefu 1,3,4
Most cancer patients succumb to disseminated disease because conventional systemic
therapies lack spatiotemporal control of their toxic effects in vivo, particularly in a compli-
cated milieu such as bone marrow where progenitor stem cells reside. Here, we demonstrate
the treatment of disseminated cancer by photoactivatable drugs using radiopharmaceuticals.
An orthogonal-targeting strategy and a contact-facilitated nanomicelle technology enabled
highly selective delivery and co-localization of titanocene and radiolabelled ﬂuorodeox-
yglucose in disseminated multiple myeloma cells. Selective ablation of the cancer cells was
achieved without signiﬁcant off-target toxicity to the resident stem cells. Genomic, proteomic
and multimodal imaging analyses revealed that the downregulation of CD49d, one of the
dimeric protein targets of the nanomicelles, caused therapy resistance in small clusters of
cancer cells. Similar treatment of a highly metastatic breast cancer model using human serum
albumin-titanocene formulation signiﬁcantly inhibited cancer growth. This strategy expands
the use of phototherapy for treating previously inaccessible metastatic disease.
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Most deadly cancers are associated with metastaticspread1, requiring systemic treatment strategies withchemotherapeutic drugs and radiation therapy. Second
generation systemic therapies rely on targeting precise molecular
signatures of cancer or invoke immune responses against certain
epitopes speciﬁc to cancer. While immensely promising, on-going
clinical trials indicate that these strategies are often associated
with life-threatening on-target, off-tumour toxicities2. For many
cancers, bone marrow is invariably involved as the point of origin
or a distant metastatic niche3. The microenvironment of the bone
marrow is laden with hematopoietic stem cells and progenitors,
making it a highly challenging niche for selective cancer cell
killing and a difﬁcult terrain for emerging systemic therapeutics.
Moreover, in advanced stages of disseminated cancers, patients
often present with extremely low total lymphocyte counts. As
such, they are stratiﬁed as severely immunocompromised and
carry the risk of poor prognosis and low overall survival rates4–7.
These patients are typically unsuitable candidates for
existing systemic therapies and emerging immunotherapies.
Photodynamic therapy or phototherapy (PT) can offer high
spatiotemporal precision and control of tumour killing through a
combination of direct cytotoxicity, immune-stimulatory, and
antiangiogenic mechanisms8. Therefore, PT could serve as an
effective therapeutic platform and a viable option for
disseminated cancers, offering an alternative treatment for
the chemotherapy-refractory disease. However, the limited
penetration of external light has conﬁned PT to the treatment of
surface accessible lesions. In addition, a priori knowledge
of tumour location is a prerequisite for initiating PT, which often
is indeterminate in the case of disseminated tumours.
An alternative approach that delivers light or stimulate
light-sensitive drugs within tissues and inside cells in vivo could
facilitate the treatment of PT-inaccessible systemic and metastatic
cancers. Clinically relevant radiopharmaceuticals are reliable
sources of Cerenkov radiation (CR) for cancer imaging9. A
decaying radionuclide could excite materials through, including
the direct interaction of electron and positron emission with
matter, particularly metals; the emission of ultraviolet-blue light
emitted by beta (β) particles, known as CR, to generate cytotoxic
reactive oxygen species (ROS); chemiluminescent reaction when
ambient ionizing radiation excites bulk water; and emission of γ
photons after the annihilation event. For simplicity, we group all
these effects as Cerenkov radiation-induced therapy (CRIT).
Therefore, a critical component of the study is to efﬁciently
harvest the diverse potential effects of radionuclides to stimulate
spatiotemporal cell death in the presence of photosensitizers.
Many drugs possess photoactive properties, but the absence of a
depth-independent photoelectronic energy source has conﬁned
their use as chemotherapeutics, preventing therapy enhancement
through a complementary phototherapeutic effect.
In this study, we hypothesize that CR-mediated conversion of
light-sensitive drugs to phototherapeutic agents will induce cell
death through pathways distinct from the ground state drug (che-
motoxicity) and in a highly selective fashion for the treatment of
diverse cancer phenotypes. Using multiple myeloma (MM) and
metastatic breast cancer models in mice, we demonstrate that
incorporating unmodiﬁed and pristine hydrophobic light-sensitive
drugs in tumour-targeted lipid nanomicelles or human serum
albumin (HSA) nanoparticles, selectively deliver the agents in
disseminated cancer cells. Subsequent in vivo administration of a
radiopharmaceutical for CRIT inhibits the proliferation of
disseminated multiple myeloma and aggressive metastatic breast
cancer cells in mice. Our treatment strategy transforms che-
motherapeutics to spatiotemporally photoactivatable drugs using
clinically relevant radiopharmaceuticals and expands the use of
phototherapy for treating previously inaccessible metastatic disease.
Results
Contact-facilitated drug delivery via VLA-4-targeted nanomi-
celles. Targeted delivery of a radionuclide and a drug is necessary
to enable co-localization in the same or adjacent cell for
subsequent activation and therapy. Once internalized by a target
cell, the radionuclide which essentially behaves as a point source
of photoelectronic energy, can excite or stimulate photoactive
materials in its vicinity (Fig. 1a). Previous studies have demon-
strated the modularity afforded by this approach in treating
cancer cells10 or subcutaneous solid tumours or mice using dif-
ferent radionuclides and photosensitizer combinations11,12.
Unlike subcutaneous solid tumour xenografts, which do not
recapitulate the physiopathology of human cancer and are trea-
table by conventional PT, most disseminated tumour models
present a different set of challenges because they are embedded in
the complex and protective microenvironment of the bone
marrow13. As a result, it would require more effective targeting
and delivery strategies to maximize cell death. We selected mul-
tiple myeloma (MM), an incurable plasma cell dyscrasia that
predominantly affects the bone marrow, spleen, and bones as the
representative orthotopic disseminated tumour model (Fig. 1a)14.
We also used PyMT-BO1 cancer cell line derived from transgenic
PyMT cancer cells as a highly aggressive metastatic breast cancer
model15 (see below).
Titanocene (TC) was used in this study as the photosensitizer
for several reasons, including its UV light excitability and
responsiveness to low radiance of CR11; biodegradability with
signiﬁcantly low cellular footprint post therapy; ease of human
translation due to its safety proﬁle in phase 2 clinical trials16; and
small size and lipophilicity, allowing integration into lipid-based
vehicles and incorporation into cell membranes post targeting. In
addition to harvesting CR luminescence, the metal centre can also
interact with radiation particles to further stress cells. However,
two fundamental challenges to TC and similar photoactive drugs,
transvascular delivery to tumour cells and cellular localization,
have remained unaddressed in the context of CRIT. In our
previous study, we used transferrin (Tf) to deliver TC to tumour
cells11. Tf has only two binding pockets for TC17,18. In the
docking process, the cyclopentadienyl (Cp) ligands of TC can be
displaced, leaving the Ti(IV) ion alone as the predominant
component that binds to the pockets17. Because both photo-
activation of Ti(IV) ion and oxidation of Cp ligand to peroxyl
radical contribute to the cytotoxicity of TC, Tf-mediated
transport of TC would potentially lower the therapeutic efﬁcacy
of Tf-TC.
ROS-mediated damage to lipid membranes is a primary mode
of action in PT19. Given the short half-lives and small diffusion
distance of some ROS, the mode of delivery of the drug to the
target cell and its proximity to the cell membrane are important
considerations for effective therapy. There is also growing
evidence that therapeutic efﬁcacy of PT can be enhanced by
selective delivery of hydrophobic photoactive drugs to the plasma
membrane compared to receptor-mediated endocytotic uptake20.
The contact-facilitated delivery of drugs to the plasma membrane
by lipid vehicles serves this purpose efﬁciently. Although
liposomal formulations can deliver drugs to cells through this
mechanism, conventional liposomes have an average diameter of
100 nm (for unilamellar vesicles) and 0.5–5 μm (for multilamellar
vesicles)21, which exceeds the physiologic upper limit of 60 nm
pore size for transvascular transport of macromolecules to ﬂow
across capillary walls of bone marrow22. To deliver pristine TC to
the plasma membrane of MM cells, we used nanoscale
unilamellar phospholipid micelles, also known as nanomicelles
(NM), as a carrier vehicle. The NM have an average diameter of
≤15 nm, which is ideal for targeting the bone marrow interstitial
space23. The upregulation of a key adhesion molecule, VLA-4
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Fig. 1 Orthogonal cancer targeting strategy using nanomicelles. a Schematic of the process of photoactivation of Titanocene in disseminated cancer cells in
the bone marrow microenvironment. The various phases are numbered: 1. Administration of targeted NM-TC; 2. The targeted NM enter the bone marrow
from the vasculature and bind to α4β1 receptor on the cancer cells and subsequently deliver the drug to the cell; 3. Administration of radiopharmaceuticals
(18FDG), which is typically 1.5–2 h after phase (1); 4. 18FDG enters the cancer cells through the overexpressed Glut transporters on cancer cells; 5. Once the
drug and radiopharmaceutical are co-localized in the cancer cells, the former is photoactivated by the latter through CR leading to cell death (6). Notice
that since the other vital cells in the bone marrow, such as stem cells and stromal cells, do not express the combination of α4β1 and glut receptors essential
for the treatment to work, they would largely remain unaffected causing minimal off-target toxicity. b Schematic of phospholipid NM with VLA-4 homing
ligands. c TEM image of micelles alone. Scale bar, 100 nm. Inset: single micelle. Scale bar, 10 nm. d Schematic of phospholipid NM encapsulating TC with
VLA-4 homing ligands. e TEM image of micelle incorporated with TC in the membrane. Scale bar, 100 nm. Inset: single NM-TC. Scale bar, 10 nm
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(α4β1 integrin), in MM provides an attractive target for precision
imaging and therapy24,25. Human MM1.S cell line is widely used
to study MM in rodents. Screening of the MM human cell line,
MM1.S, using anti-CD49d (α4) and CD29 (β1) antibodies
showed a ≥95% expression level of VLA-4 (Supplementary
Figure 1). We loaded the NM with LLP2A (Supplementary
Figure 2a), a small molecule peptidomimetic that binds VLA-4
with an exceptionally high afﬁnity (IC50 = 2 pM)26. LLP2A was
synthesized on a solid support, followed by conjugation to
phospholipids (DSPE) engrafted with polyethylene glycol (PEG)
chains to improve circulation in blood (see “Materials and
Methods' section for details; Supplementary Figure 2b, c). The
NM were generated as a microﬂuidized suspension containing
LLP2A-PEG-DSPE and TC. Control NM that excluded the
homing ligand LLP2A or TC were also prepared (Fig. 1b, c).
An average size distribution of NM with and without TC was
14.7± 2 nm and 11.9± 0.5 nm, respectively, with an average
polydispersity index of 0.2 (Table 1).
We successfully loaded 0.19 mgmL−1 of TC in the NM
(Table 2). Based on the full-width half-maximum of the NM size
distribution (about 15 nm), the volume of NM, and the net
concentration of TC per volume of NM using inductively coupled
plasma optical emission spectrometry, we determined the average
number of TC per NM as 3 (range, 2–5). The incorporation of TC
in the lipid layer was conﬁrmed by electron microscopy (Fig. 1d,
e). The metallic titanium (Ti) centre in TC rendered the vesicles
electron dense in contrast to the control vesicles without TC.
Upon addition into the NM, TC incorporated in the interface
between the lipid and the hydrophilic layers, as evidenced by
electron microscopy (Fig. 1d, e). Probably, the hydrolysis of TC
dichloride to the dihydroxyl derivative in aqueous medium17
created an amphiphilic structure, favouring the orientation of the
two cyclopentadienyl and dihydroxyl moieties toward the
hydrophobic core and the outer hydrophilic segment, respec-
tively. Incorporation of LLP2A did not destabilize the NM and
the presence of unnatural amino acids conferred protease
resistance and high plasma stability on the nanosystem26.
In vivo pharmacokinetics of VLA-4-targeted nanomicelles. In
vivo pharmacokinetic (PK) proﬁle of the NM-TC was studied in
naive rats. A plasma half-life of 123 min was obtained after
systemic administration (Fig. 2a). We performed the PK in rats
instead of mice to obtain sufﬁcient blood sample for serial
measurements of TC concentration in the same animal.
Otherwise, the small volume of blood in mice would require us to
pool samples from different mice, masking inter-specimen
variability. Although the PK value in mice are expected to be
shorter than rats, the information allowed us to estimate half-life
of TC in rodent blood. The NM in circulation remained intact
in vivo, until cleared or destroyed. However, the micelles have a
limited half-life and must reach their target early before
elimination.
VLA-4-targeted nanomicelles delivers TC to MM-avid organs.
The selectivity of LLP2A to MM cells and the serum stability of
the NM in delivering the TC was determined by in vivo
biodistribution analysis. Using inductively coupled plasma optical
emission spectrometry, we determined the Ti metal content
ex vivo in organ samples from an orthotopic disseminated MM1.
S/SCID model. We compared the biodistribution of NM-TC,
Tf-TC and MKT4, a water soluble analogue of TC that was used
in phase 1 and phase 2 clinical trials16,27 at 90 min post injection.
The choice of 90 min time point is based on rat PK data, which
showed a t1/2 of 123 min in rats but the rate of clearance after 90
min approached stasis, probably representing the contribution of
an intraversation process of drug from tissues to blood (Fig. 2a).
Although this time point is expected to be shorter in mice, we
chose 90 min for the mouse study to ensure that the blood
concentration of TC is sufﬁciently low, to prevent potential
systemic toxicity, but not too late when the amount in tumour
tissue is small. In mice administered with NM-TC, the highest Ti
concentrations were found in skeletal tissue and spleen,
which typically house MM cells, with relative values of 115± 7
and 52± 9.5 μg g−1, respectively (Fig. 2b). In comparison, the
uptake of MKT4 was lower in tumour sites, with values of 53± 9
and 16± 4 μg g−1, for skeletal tissue and spleen, respectively
(Fig. 2b). Similarly, the accumulation of TC in these tissues for
mice treated with Tf-TC was only 27.5± 6 and 14± 1 μg g−1,
respectively. These results demonstrate the advantage of using
NM to deliver TC to MM target organs. Previous studies have
suggested that the cylopentadienyl rings in TC, which assists in
stabilizing the Ti(IV) ion in a monomeric form, are lost in MKT4
and Tf-TC17,18. Thus, sequestration of TC in the hydrophobic
region of NM may help stabilize the drug and minimize rapid loss
from target tissues.
CRIT inhibits tumour growth in disseminated MM mouse
model. We used an FDA approved and clinically employed
radiopharmaceutical, 18FDG (t1/2 = 109.8 min), as a source of
photoelectronic energy28. The radiopharmaceutical, which is
currently the gold standard for clinical imaging of MM29,30,
targets metabolically active tumours via the glucose transporter
(GLUT1) protein. By using an orthogonal-targeting GLUT1 and
VLA-4 strategy to, respectively, deliver the 18FDG and NM-TC to
the MM cells, we aimed to minimize the potential saturation or
depletion of the targeted receptors. In healthy subjects, 18FDG
uptake is low in the bone marrow and spleen, but signiﬁcantly
higher in malignancy, inﬂammation or after administration of
hematopoietic growth factors31. Using small animal positron
emission tomography (PET) of MM in mice, we found more than
twofold uptake of 18FDG in bones compared to naive mice
(Fig. 2c–i).
The performance of CRIT in a disseminated MM1.S/ SCID
mouse model was tested. Based on the biodistribution data,
sequential tail vein injections of NM and then 18FDG were spaced
Table 1 Size distribution of the nanomicelles
Sample Hydrodynamic diameter (nm) Polydispersity index Zeta potential (mV)
Nanomicelle + LLP2A 11.9± 0.5 0.217 −0.81
TC nanomicelle + LLP2A 14.7± 2 0.241 2.12
Table 2 Metal (Ti) and TC content in nanomicelles and HSA




TC nanomicelle 0.52 0.192
TC-HSA 21.65 5.613
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90 min apart to activate TC in tumours. Treatment was repeated
four times at an interval of 1 week, and the disease progression
was monitored weekly by bioluminescence imaging (BLI; Fig. 3a).
A week interval was chosen for treatment for several reasons that
include the need to allow the mice to fully recover from the
treatment; account for full decay cycle of 18FDG; consider
logistical reasons such as tail vein recovery; and allow sufﬁcient
time for imaging time points between treatment sessions. In the
control groups consisting of untreated mice or those treated with
either NM or 18FDG alone (Fig. 3b, c), we observed an
exponential increase in the BLI signal over several weeks,
demonstrating the systemic progression of the disease and
indicating the primary involvement of the spleen and skeletal
tissues. In contrast, mice treated with NM-TC and 18FDG showed
a conspicuous decrease in the disease progression, suggesting the
effective targeting and response of MM1.S to CRIT. Survival
studies revealed a signiﬁcant advantage of the CRIT over the
control groups with 50% surviving up to about 90 days compared
to about 62 days for the control groups (Fig. 3d). Correlative
18FDG-PET imaging conﬁrmed the lower tumour burden in
CRIT-treated mice compared to the control groups (Fig. 3e, f).
The mice were killed after they developed hind limb paralysis
resulting from spinal cord and spinal vertebral involvement. The
treated mice eventually succumbed to cancer due to the remnant
MM cells that could not be completely eradicated by CRIT.
CRIT selects for α4-deﬁcient multiple myeloma cells in vivo.
Residual cancer cells that escaped treatment appeared focal and
conﬁned at random sites within the major bones, particularly the
vertebrae (Fig. 3b, e). These localized cancer cells continued to grow,
albeit at a slow rate. The surviving cancer cells were subsequently
extracted from the mice and reintroduced into a fresh group of naive
SCID mice to determine response to when treated with CRIT.
However, BLI (Fig. 4a) and 18FDG-PET did not show noticeable
differences between the treated and untreated groups, suggesting the
cells were resistant to CRIT. These CRIT-resistant MM1.S (MM1.
SCRIT-RES) cells were harvested and analysed for the expression
levels of GLUT1, α4 and β1 integrins to determine whether uptake
of 18FDG by GLUT1 or α4β1 binding of the NM were compro-
mised. GLUT1 mRNA (Fig. 4b) or β1 cell surface expression
(Fig. 4c, d) analyses did not demonstrate signiﬁcant difference
between the parental MM1.S and the MM1.SCRIT-RES cells. How-
ever, the MM1.SCRIT-RES cells expressed lower cell surface α4 than
parental MM1.S cells (Fig. 4e, f). Flow cytometry analysis demon-
strated that LLP2A-Cy5, which selectively binds VLA-4 with high
afﬁnity32, did not internalize in the MM1.SCRIT-RES cells compared
to the parental MM1.S cells (Fig. 4g, h). These results suggest that
the MM1.SCRIT-RES cells had downregulated the expression of α4
(CD49d), possibly impairing the binding of the LLP2A functiona-
lized NM to some MM cells. Unlike in vitro studies where static
incubation of nanoparticles can abrogate speciﬁc binding of
receptor-targeted materials, the in vivo dynamics and the relatively
small number of these resistance cells in the initial tumour popu-
lation could have favoured the homing of NM-TC to the VLA-4
positive cells in mice. As a result, CRIT could have preserved a
subclone of MM1.S with low α4 that was present at low frequency in
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Fig. 2 Monitoring nanomicelles biodistribution and spread of multiple myeloma in vivo. a Pharmacokinetics of NM-TC in rats using coupled plasma optical
emission spectrometry. Half-life is 123.4min. b Comparison of biodistribution in mice of targeted NM-TC and pristine TC in vivo showing highest uptake
and retention in bones and spleen, characteristic of multiple myeloma, 2 h post injection. 18FDG-PET images showing increased uptake of 18FDG in mouse
forelimbs, spine, and hind limbs of mice with multiple myeloma (c, e, g) compared to naive mice (d, f, h, i). Comparison of standard uptake values (SUV) of
18FDG in multiple myeloma vs. naive mice in various bones. Values are means± s.e.m. *P< 0.05, **P< 0.01. n= 5 mice for each of the pharmacokinetics
study in rats; and biodistribution study in mice
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Fig. 3 Response of multiple myeloma to CRIT. a Timeline of treatment. b Bioluminescence imaging of representative multiple myeloma-bearing mice in
different treatment groups—untreated, 18FDG, NM controls and CRIT. All images are dorsal images and on the same scale. The images of control groups
appear saturated on week 6 in comparison to CRIT. c Change in bioluminescence intensity as a result of treatment compared to untreated control. The
intensity consistently remains lower than untreated controls during the treatment and beyond. d Comparison of survival of different treatment groups
showing a twofold increase in survival in treated mice compared to control groups. **P< 0.01. e 18FDG-PET images of MMmice before and after treatment
showing lower tumour burden in the latter. F: frontal view, S: sagittal view. Boxes denote tumour region. f SUV values of the treatment group were lower
than untreated controls. **P< 0.01. n= 15 mice for CRIT, n= 10 mice for untreated control and n= 5 mice for NM-TC alone and 18FDG alone treated mice
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the subset of MM1.S cells with low CD49d expression levels and low
levels of the activated conformation of VLA-4. A potential approach
to achieving complete eradication of MM cells is to identify com-
plementary biomarkers that allow the delivery of TC-loaded NM to
all MM1.S cells or through the use of combination therapy that
more effectively targets and eliminates both CRIT-responsive MM1.
S and MM1.SCRIT-RES cells in vivo.
CRIT preserves normal hematopoietic stem cells. An important
consideration during CRIT is to preserve and sustain the long-
term viability of the hematopoietic stem cells and progenitor cell
population in the bone marrow. Clonogenic assays of normal
bone marrow progenitor cells extracted from mice treated with
CRIT did not reveal a signiﬁcant change in colony-forming units
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bone marrow repopulation experiments showed that there was no
detrimental effect of CRIT on the primitive hematopoietic stem
cell compartment33. The 2-month hematopoietic reconstitution
of mice transplanted with bone marrow from wild-type vs. CRIT-
treated mice was not signiﬁcantly different, suggesting that there
was no obvious reduction in engrafting hematopoietic stem cell
population after treatment with CRIT (Fig. 4j, k).
HSA-TC nanoparticles deliver drug to metastatic breast cancer.
We extended the use of CRIT in a metastatic breast cancer model.
PyMT-BO1 cell line is a highly aggressive breast cancer cell line
derived from transgenic PyMT breast cancer mice15. Previous
reports have demonstrated that rapidly proliferating tumour cells
actively internalize albumin for use as a source of nitrogen and
energy, partially accounting for the formulation of drugs in
albumin or its nanoparticles for drug delivery to tumours34–36.
Thus, formulation of hydrophobic drugs, such as TC in albumin,
will not only enhance solubilization in an aqueous medium, but
also mediate delivery to tumours. We mixed TC (80 mg) in an
aqueous solution (16 mL) containing 0.5% human serum albumin
(HSA) for 6 h before lyophilizing the entire mixture (see 'Mate-
rials and Methods' section). We used a low concentration of HSA
in this formulation to prevent potential immunogenic response in
mice. The lyophilized product was reconstituted in 0.9% saline
immediately before use. Using inductively coupled plasma mass
spectrometry, we determined the concentration of TC in the
reconstituted sample as 5.6 mgmL−1 (Table 2). The correspond-
ing concentration of HSA in the formulation was 8.95 mgmL−1,
as determined by using a protein assay. Dynamic light scattering
(DLS) measurements indicate that the HSA-TC nanoparticles
were fairly monodispersed with an average size of 12–15 nm
(Supplementary Figure 3). About 1.5% of the particles formed
large aggregate clusters of 100 nm, creating a bimodal distribution
that skewed the z-average diameter (120 nm) and polydispersity
index (0.278). Electron microscopy size measurement correlated
with the DLS results, showing mostly monodispersed HSA-TC
nanoparticles of 10–15 nm in diameter (Supplementary Figure 4),
along with few aggregates of 30–90 nm. The HSA nanoparticles
allowed us to load high concentration of the hydrophobic TC per
volume of aqueous solution for subsequent delivery to metastatic
breast cancer.
Biodistribution of HSA-TC in metastatic breast cancer model.
Intracardiac injection of PyMT-BO1 cells stably transfected with
GFP-ﬁreﬂy luciferase in mice-induced bone metastases, especially
to the lower limbs and other major organs (Fig. 5a, b). By day 10,
the tumour burden was very high, requiring immediate killing
(Supplementary Figure 5). For the biodistribution study, we
reconstituted the lyophilized HSA-TC in saline and administered
100 µL of 0.6 mg per 20 g mouse. Both the non-invasive in vivo
(Fig. 5b) and the ex vivo (Fig. 5c) BLI analysis showed that the
tumour cells disseminated to most major organs, including the
vertebrae and lower limbs. Quantitative analysis of the Ti con-
tents in tissue samples from blood and lower limbs by inductively
coupled plasma mass spectrophotometry showed the highest
accumulation of the metal in the limbs at 3 h post injection of
HSA-TC (Fig. 5d). The concentration of Ti in the lower limbs
decreased gradually over time (p< 0.05). At 24 h, the Ti content
from the HSA-TC in the limbs was indistinguishable from the
background content. We had to subtract the background Ti from
untreated mice to determine the contribution of HSA-TC because
most mouse feedstock contains Ti products.
HSA-TC inhibits growth of metastatic breast cancer in mice.
We explored the feasibility of using CRIT to inhibit tumour
growth in the highly metastatic PyMT-BO1 GFP/Luc breast
cancer model in C57B6 mice. Our biodistribution data indicate
that the accumulation of TC in the cancer-homing organs is
highest at about 3 h post injection of HSA-TC. 18FDG (50–60 µL;
800 µCi per mouse) was administered intraperitoneally at 2 h
after the intravenous administration of HSA-TC. We chose
intraperitoneal instead of intravenous route for 18FDG injection
to maintain consistency across the experiments because of the
difﬁculty of ﬁnding viable tail veins in the same mouse for
multiple injections of both HSA-TC and 18FDG. Comparison of
different routes of 18FDG administration in mice determined that
the SUV of 18FDG injected intraperitoneally in tumours is opti-
mal at about 1 h post injection, and is similar to intravenous route
at closer to this time point37,38. We hypothesized that adminis-
tering the radionuclide at about 2 h after injection of the HSA-TC
(100 µL of 0.6 mg per 20 g mouse) will achieve maximum accu-
mulation of both CRIT effectors in tumours after 3 h. Three
treatment cycles of HSA-TC and 18FDG were administered
2 days apart starting from day 2 after initiating the metastatic
disease when the tumours are observable by BLI (Supplementary
Figure 5). Groups with no treatment, treatment with HSA-TC
alone and 18FDG alone served as controls. Whole-body luciferase
activity from day 2 to day 9 were analysed for tumour cell pro-
liferation. Compared to the untreated mice (Fig. 6a), a small
decrease in BLI signal was observed in the HSA-TC (Fig. 6b) and
18FDG (Fig. 6c)-treated mice compared to the untreated cohort.
However, the pattern of tumour growth in all the three control
groups was similar. In contrast, the CRIT group showed sig-
niﬁcant tumour stasis, with a few focused cluster of tumour cells
that did not respond to the therapy (Fig. 6d, e). The slow growth
and focal nature of the CRIT-resistant cells suggests that this
therapeutic method can transform metastatic cancer into a sur-
gical disease. Whereas PyMT-BO1 model is an excellent model
for the rapid evaluation of drugs or treatment methods, all the
animals eventually died or were killed between day 9 and 12 due
to the aggressiveness of this model. The fast death cycle prevents
longitudinal evaluation of each animal, which is needed to obtain
Fig. 4 CRIT selects for CD49d cells in MM model. a Bioluminescence intensity plot showing resistant nature of MM cells extracted from treated cohort
(MM1CRIT-RES) upon rechallenging with CRIT in fresh mice. b No difference in GLUT1 mRNA expression was observed between parental MM1.S cells and
resistant MM1.SCRIT-RES cells as assessed by qRT-PCR. ns not signiﬁcant. c–h No difference in expression of CD29 was observed between MM1.S cells (c)
or MM1.SCRIT-RES cells (d) following treatment with CRIT in vivo. MM1.S stopped responding to CRIT by downregulating expression of VLA-4 subunit
CD49d (Resistance= 28.12% CD49d+) (f) relative to parental cells injected into mice at the beginning of the experiment (parental= 99.92% CD49d+)
(e), resulting in reduced binding of the VLA-4-targeting ligand LLP2A on resistant cells (h) (LLP2A+= 6.6%) compared to parental MM1.S (g)
(LLP2A+= 84.15%). i No signiﬁcant difference in colony-forming units of progenitor stem cells was observed between untreated, control and treated mice. j
To determine if CRIT reduced engraftment of haematologic cells in vivo, we assessed BM repopulation following CRIT treatment. Bone marrow from
treated mice or PBS-treated controls were mixed with congenic B6.CD45.1/2 at a ratio of 1:1 before infusion of 1 × 106 total BM cells into lethally irradiated
(TBI 1100 cGy) B6.CD45.1 recipients. k Percentage of cells derived from treated donor BM (CD45.2) were calculated as a percentage of total donor BM
(CD45.2 + CD45.1/2). BM from CRIT-treated mice effectively repopulated recipients (n= 5 per group)
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reliable survival plots. Future studies will explore different models
and establish the mechanism of therapy resistance in this cancer
cell line.
In summary, we have successfully demonstrated the applica-
tion of PT for treating disseminated malignancies using VLA-4-
targeted NM and HSA-TC nanoparticles, activated by radio-
pharmaceuticals. Integral to this strategy is the availability of a
wide range of radionuclides for clinical PET imaging and
preclinical Cerenkov luminescence imaging to further monitor
and guide treatment response39,40. We demonstrated a strategy to
rescue abandoned light-sensitive drugs with poor therapeutic
outcomes such as TC and some FDA-approved drugs with
inherent photoactivity into precision phototherapeutics. In
addition, clinical biochemistry parameters and histopathologic
assessment of vital organs in the treated and untreated controls
were similar (Supplementary Figure 6 and Supplementary
Figure 7). The brain, heart, liver and kidneys were of particular
interest because 18FDG naturally accumulates in these organs
because of their high glucose utilization and elimination
pathways. The absence of off-target toxicity to normal hemato-
poietic stem cells may favour the translation of this approach in
the clinic as either a standalone therapy or as a combination with
other therapies, including chemotherapy, where the suppression
of the bone marrow and the risk of pancytopenia may not be
anticipated to be greater than those patients receiving che-
motherapy without CRIT. Our results suggest that the sequential
administration of the NM-TC and radionuclide minimizes the
association of both therapeutic components in vital organs. These
ﬁndings expand the potential use of PT for treating previously
PT-inaccessible metastatic, infectious and cardiovascular diseases.
Methods
Synthesis and characterization of VLA-4-targeted titanocene micelles. The
VLA-4 ligand, LLP2A (Supplementary Figure 2a), was prepared on solid support
using standard ﬂuorenylmethyloxycarbonyl (Fmoc) peptide synthesis as reported
previously41. Starting with Rink Amide resin, serial Fmoc deprotection cycles were
achieved with 20% piperidine in dimethylformamide (DMF) and coupling of
amino acids was performed with hydroxy-benzotriazole (HOBt) and 1,3-diiso-
propylcarbodiimide (DIC) in DMF at 25 °C. The crude product was cleaved from
the resin with a mixture of 95% triﬂuoroacetic acid (TFA): 2.5% water: 2.5%
triisopropylsilane and precipitated with cold diethyl ether. The product was pur-
iﬁed by RP-HPLC and characterized by analytical HPLC and ES-MS: calculated
mass for LLP2A is 1084.27 Da; observed mass is 1085 Da (Supplementary Fig-
ure 2b). To incorporate LLP2A into nanomicelles, LLP2A was dissolved in ethanol
and mixed with 2-iminothiolane in methanol. After reacting for 2 h at 25 °C,
polyethylene glycol2000-phosphatidylethanolamine (PEG-PE) was added to the
mixture and incubated for another 2 h. The product was puriﬁed using 3000 Da
MWCO dialysis tubing to dialyse off the free LLP2A, and lyophilized to give a
white solid (LLP2A-PEG-PE). The product was characterized by analytical HPLC
and ES-MS: average calculated mass for LLP2A-PEG-PE is about 4100 Da;
observed mass is about 4065 Da (Supplementary Figure 2c). The phospholipid/
polysorbate 80 micelles were prepared as a microﬂuidized suspension comprising
20% polysorbate Tween 80 (v/v), a 2.0% (w/v) surfactant commixture and 1.7% (w/
v) glycerine in ﬁltered MilliQ Nanopure water. The surfactant co-mixture were 0 or
2 mole% TC and 0 or 0.15 mole% of LLP2A-PEG-PE, with the remainder as
phosphatidylcholine (>98% purity, NOF America). The surfactant components
were dried from organic solvent into a ﬁlm, resuspended in nanopure water, and
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Fig. 6 Representative BLI of PyMT-BO1 GFP/Luc metastatic breast cancer cells in C57B6. a Untreated C57B6 mouse bearing highly metastatic PyMT-BO1
cancer. Accumulation in the lower limbs were predominant. b Mouse treated with 30mg kg−1 of HSA-TC nanoparticles. c Mouse treated with 800 µCi of
18FDG. d Mouse treated with a combination of HSA-TC and 800 µCi 18FDG. e Quantiﬁcation of whole-body luminescence in CRIT-treated mice compared
to untreated, HSA-TC treated or 18FDG-treated controls (*P values are 0.038, 0.23 and 0.017 for CRIT, HSA-TC alone and 18FDG alone, respectively). BLI







































































Fig. 5 Dissemination of metastatic breast cancer cells and biodistribution of TC in mice. a In vivo BLI non-tumour-bearing C57BL/6J mice. b In vivo BLI of
metastatic breast cancer 10 days post intracardiac injection of PyMT-BO1 GFP/Luc in C57BL/6J mice. c Ex vivo BLI of metastatic tumour burden 10 days
post tumour initiation. The left panel are tissues obtained from a mouse and the right panel are tissues obtained from b mouse. d Inductively coupled
plasma mass spectrometry analysis of Ti content in blood samples and the lower limbs, where tumour burden is high. The Ti content was background-
corrected from untreated mice; *P< 0.05. Studies were performed with n= 5 mice per each group
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C for 3 min and then microﬂuidized (LV1, Microﬂuidics, Inc) at 20,000 psi for ﬁve
passes. The micelles were ﬁltered with a 0.2 µm ﬁlter into sterile serum vials,
preserved under inert gas, capped and crimp-sealed before storage at 4 °C for
subsequent use. The concentration of TC in TC nanomicelles was determined by
inductively coupled plasma optical emission spectrometry (PerkinElmer Optima
5300). For each measurement, 20 µL reconstituted TC nanomicelle (n = 3) was
digested with concentrated nitric acid in Mars 6 Microwave Digestion System
(CEM Corporation). Microwave power was ramped up to 200 °C for 20 min fol-
lowed by a hold for 20 min at the same temperature. All external calibration
standards of 0.01, 0.1, 1.0, 10, 50, 100 and 200 µg L−1 were within 10% of expected
concentration. Relative standard deviation measurements were less than 5% for all
standards and the samples.
Dynamic light scattering measurements were acquired with a Zeta Plus Zeta
Potential Analyzer (Brookhaven Instruments Corporation, Holtsville, NY)
equipped with a 633 nm laser. Three measurements were conducted in deionized
water for each sample with at least 10 runs and each run lasting 10 s. All sizes
reported were based on intensity average. For negative staining and electron
microscopy analysis of NM, samples were allowed to absorb onto Formvar/carbon-
coated copper grids for 10 min. Grids were washed two times for 1 min each in
dH2O and stained with 1% aqueous uranyl acetate (Ted Pella Inc., Redding CA) for
1 min. Excess liquid was gently wicked off and grids were allowed to air dry.
Samples were viewed on a JEOL 1200EX transmission electron microscope (JEOL
USA, Peabody, MA) equipped with an AMT 8-megapixel digital camera
(Advanced Microscopy Techniques, Woburn, MA).
Synthesis and characterization of HSA-TC. TC (80 mg) was added in an aqueous
solution (16 mL) containing 0.5% HSA. The mixture was shaken moderately at 560
oscillation per min in IKA KS 130 basic plate shaker for 6 h at room temperature,
followed by lyophilization in Thermo Fischer SAVANT RVT5105 refrigerated
vapour trap lyophilizer to obtain the HSA-TC as dry powder. The lyophilized
product was reconstructed in 0.9% saline immediately before use. The con-
centration of the TC in the reconstituted injection was 5.6 mg mL−1 (characterized
by inductively coupled plasma optical emission spectrometry and that of HSA in
the reconstituted solution was 8.95 mgmL−1 (determined by Bio-Rad Quick Start
Bradford Protein Assay kit). The size and dispersity of the HSA-TC was conﬁrmed
by DLS (Malvern Zetasizer nano Series) and electron microscopy (JEOL TEM-1400
electron microscope).
Cell culture. All cell lines underwent STR proﬁling and tested for mycoplasma
contamination. MM1.S-Luc cells were cultured in RPMI1640 medium containing
10% heat-inactivated FBS and 2 mercaptoethanol (50 μM ﬁnal) and 1× of all of the
following: penicillin/streptomycin (100 μg mL−1 ﬁnal), sodium pyruvate (1 mM
ﬁnal), non-essential amino acids, HEPES (10 mM ﬁnal) and L-glutamine. A similar
condition was used to culture PyMT-BO1 cells in DMEM media plus 10% FBS.
Tumour models in mice. All animal studies were conducted in compliance with
the guidelines established by the Animal Studies Committee at Washington Uni-
versity in St. Louis, Missouri. Fox Chase SCID Beige mice (4-week, female) were
purchased from Charles River laboratories for developing the disseminated MM
model. C57BL/6J mice (6-week, female) were purchased from the Jackson
Laboratory for developing the metastatic breast cancer model. MM1.S-Luc cells
(1 × 106 in 100 µL per mouse) were injected intravenously for the MM model and
PyMT-BO1-GFP-Luc cells (1 × 105 in 50 µL per mouse) were injected in the left
ventricular chamber for the breast cancer model. BLI was used to monitor cell
viability and tumour burden.
Bioluminescence imaging. Ex vivo and in vivo bioluminescence imaging of MM1.
S-Luc in SCID mice and PyMT-BO1 GFP/Luc in C57BL/6J was performed on an
IVIS Lumina (PerkinElmer, Waltham, MA; Living Image 4.3, 5 min to 1 s exposure,
bin2–8, FOV12.5 cm, f/stop1, open ﬁlter). Image analysis was performed using
Living Image 2.6 software. For in vitro imaging, optimal bioluminescence for
subsequent in vivo studies was determined by plating 1 × 105 cells in a black 24-
well plate. Fixed regions of interest (ROIs) were drawn on each well and images
captured after an exposure time of 10 s. A radiance >1 × 108 photons s−1 cm−2 sr−1
was considered as the threshold. For in vivo imaging, mice were injected intra-
peritoneally with D-luciferin (150 mg kg−1 in PBS; Gold Biotechnology, St. Louis,
MO) and imaged after anaesthetizing with isoﬂurane (2% vaporized in O2). Total
photon ﬂux (photons s−1 cm−2 sr−1) was measured from ﬁxed ROIs over the entire
mouse.
Pharmacokinetics of NM-TC in rats. For pharmacokinetic analysis, the NM at a
dose of 25 μL kg−1 was administered intravenously to rats (n = 5) and serial blood
samples were drawn at 1, 5, 15, 30, 60, 90, 120 and 1440 min for metal analysis. The
PK in rats is done to allow enough sample for serial measures in the same animal.
Otherwise, blood samples must be pooled, masking inter-specimen variability.
Brieﬂy, animals are weighed, anesthetized and shaved on the ventral side of the
neck. The surgical area is cleaned and wiped free of hair before surgery. Following
stabilization, the incision site is anesthetized, and an incision made just off midline
to the trachea through the skin. The carotid artery is exposed by blunt dissection
and snared with two ligatures, one proximal one distal, for introducing the
catheter. The wound is wetted periodically with lidocaine (2%)/bupivicaine (2.5%)
and saline to maintain analgesia. The distal tie is tightened to ligate the artery, and
the proximal tie is made into a Potter’s knot. A silastic catheter is inserted through
an arteriotomy and secured in place with the ligatures. The catheter is then ﬂushed
with heparinized saline. Blood is sampled via a carotid catheter. Blood samples
were ~150 μL and ﬂushed with equivolume of saline. The blood samples were
digested by microwave digestion in HNO3/H2O2 under pressure and the con-
centration of TC (mgmL−1) was determined by inductively coupled plasma optical
emission spectrometry and reported as percentage of injected dose per gram of
tissue (ID g−1).
Biodistribution of NM-TC in mice. The NM-TC at a dose of 50 μL per mouse
were administered intravenously in MM1.S (n = 5) tumour-bearing mice. A one-
time dose was administered 30 days post cell injection of MM1.S cells. Tf-TC and
MKT4 were prepared as described in the literature18. Brieﬂy, MKT4 was prepared
by adding ﬁvefold molar excess of mannitol (500 mg) to TC (100 mg) and a 19-fold
molar excess of sodium chloride (450 mg) in 50 mL water. The solution was mixed
in a shaker at 25 °C for 4 h before lyophilizing. For intravenous injections, MKT4
was reconstituted in saline at a dose of 0.25 mg kg−1. To prepare Tf-TC, ﬁvefold
molar excess of TC was added to human apo-Tf and incubated in a shaker for 2 h
at 25 °C. A working stock of TC was initially prepared in DMSO due to low
solubility of TC in water and aqueous buffers. The mixture was then dialysed
overnight against DPBS using a 3000 Da molecular weight cutoff (MWCO) Slide-
A-Lyzer MINI Dialysis Devices to remove excess TC. MKT4 and Tf-TC were
administered intravenously at a dose of 0.25 mg kg−1 (normalized to the TC
content in NM) in MM1.s-SCID mice (n = 5). The mice were then killed 90 min
post injection and the organs were dissected. The organs and blood were processed
by microwave digestion in HNO3/H2O2 under pressure and the TC measurements
were measured in mgmL−1 by inductively coupled plasma optical emission spec-
trometry and adjusted to %ID g−1 tissue.
Biodistribution of HSA-TC in mice. A similar procedure described above was used
in the HSA-TC study. HSA-TC (50 µL per mice, 30 mg kg−1) was injected intra-
venously in C57B6 mice on day 10 post intracardiac injection of PyMT-BO1 GFP/
Luc breast cancer cells. In addition to the untreated group, each group of ﬁve mice
were killed at 1, 3, 6 and 24 h post injection after BLI of the living animal. The
organs and blood were harvested and imaged ex vivo using BLI to estimate the
tumour distribution. To determine uptake of the Ti distribution, blood and lower
limbs at the different time points were were digested by microwave in HNO3/H2O2
under pressure and analysed by inductively coupled plasma mass spectrometry.
The Ti content in each tissue were measured in mgmL−1 after subtraction of
background Ti from the untreated cohorts.
18FDG-PET imaging. 18FDG-PET imaging was performed on MM mice 30 days
post cell injection (n = 4) along with naive mice (n = 4). The mice were fasted for 6
h before each scan. After anesthetizing the mice with 1.5–2% isoﬂurane and oxy-
gen, 0.19 mCi (7.03 MBq) 0.1 mL−1 of FDG was administered intravenously. A 10-
min transition scan was performed just before the 10 min emission at 1 h post
injection using a MicroPET-Inveon MultiModality scanner (Siemens Preclinical
Solutions, Erlangen, Germany). The animals were placed on the microCT® in the
same position to obtain anatomical imaging and co-registered to the microPET®
image. The data were analysed using Inveon Research Workstation software, by
manually drawing three-dimensional ROI from PET images using CT anatomical
guidelines. The activity associated with tumour was measured and maximum SUVs
were calculated using SUV = ([mCi mL−1] x [animal weight (g)]/[injected dose
(mCi)]).
In vivo CRIT in disseminated MM1.S-luc/SCID mouse model. After MM1.S cell
injection, considered day 1, mice were imaged weekly using BLI for 7–9 weeks.
Treatment was initiated on day 5. Mice were administered 50 μL of NM-TC (0.25
mg kg−1 TC) intravenously followed by 29.6 MBq 0.1 mL−1 of 18FDG 90 min later,
also administered intravenously (n = 15). Control mice (n = 5 per group) were
administered with NM-TC or 18FDG alone. A total of four treatment cycles at an
interval of 1 week were given per animal, where a cycle refers to an administration
of NM-TC and 18FDG. BLI and survival of these groups of mice were tracked along
with untreated controls (n = 10) on a weekly basis. Food was withheld from mice
for 6 h before administering 18FDG and kept in a dark, lead-shielded room post
injection. The weight and any physical signs of distress were also monitored closely.
The mice were killed by cervical dislocation after anaesthesia with 5% isoﬂurane
when there was a loss of >20% total body weight. For rechallenging studies on
resistant MM1 cells (MM1CRIT-RES), the bone marrow (BM) was harvested from
treated mice when whole-body radiance exceeded 5 × 104 photons s−1 cm−2 sr−1.
BM was harvested by ﬂushing the femoral shaft with PBS and reinjecting the cells
into a fresh set of Fox Chase SCID Beige mice. The treatment schedule followed
was similar to MM1.S described above. BLI was used to track and compare
treatment response in a CRIT group (n = 10) and an untreated group (n = 10).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02758-9
10 NATURE COMMUNICATIONS |  (2018) 9:275 |DOI: 10.1038/s41467-017-02758-9 |www.nature.com/naturecommunications
In vivo CRIT in metastatic breast cancer PyMT-BO1 model. A similar procedure
described above was followed in the HSA-TC CRIT study. On day 2 post intra-
cardiac injection of PyMT-BO1-GFP-Luc cells in C57BL/6J mice, BLI was used to
conﬁrm tumour viability and engraftment. The mice were stratiﬁed into the fol-
lowing groups: untreated control, HSA-TC only, 18FDG only and combination of
HSA-TC and 18FDG cohorts. Each group has ﬁve mice weighing between 18 and
20 g. All mice were fasted 3 h before commencing the treatment on day 2. HSA-TC
(100 µL per mice, 30 mg kg−1 was injected intravenously in the HSA-TC and HSA-
TC + 18FDG groups. This was followed by intraperitoneal (i.p.) injection of the
18FDG (800 µCi in 50 µL saline containing 0.02% ethanol) in the 18FDG-only
group and the HSA-TC + 18F FDG group after 2 h from the drug injection. This
treatment regimen was performed every 2 day for 3 times and BLI images were
captured ﬁrst on each occasion before the therapy. Tumour response was quan-
tiﬁed using both whole body and then lower limb signals from BLI.
RNA analysis. Bone marrow was ﬂushed from femurs using cold PBS and single
cell suspensions were prepared by ﬁltering through a 40 μm nylon strainer. Red
blood cells were lysed using Red Blood Cell Lysing Buffer (Sigma-Aldrich) and
washed with cold PBS. MM1CRIT-RES cells were sorted by ﬂuorescent-activated cell
sorting for GFP. RNA was extracted from MM1CRIT-RES cells using the Qiagen
RNAeasy mini kit according to the manufacturer’s instructions. cDNA was syn-
thesized using qRT-PCR was performed on the Applied Biosystems StepOnePlus
Real-Time System (Thermo Fisher) using pre-designed TaqMan® Gene Expression
Assays (Life Technologies; 18S RNA Hs99999901 and glut1 Hs00892681)
according to the manufacturer’s instructions. The ΔΔCT method was used to
calculate changes in fold expression and results were analysed with GraphPad
Prism 6.
Flow cytometry. Red blood cells in the ﬂushed BM were lysed using Red Blood
Cell Lysing Buffer (Sigma-Aldrich) and washed with cold PBS. Cell subsets were
evaluated by ﬂow cytometry by re-suspending the cells in staining buffer (PBS
supplemented with 0.5% bovine serum albumin and 2 mM EDTA) and incubating
for 30 min at 4 °C with pre-titrated saturating dilutions of the following
ﬂuorochrome-labelled monoclonal antibodies: CD49d-PE/Dazzle594 (clone 9F10;
Biolegend), CD29-APC (clone TS2/16; Biolegend), human CD45-Alexa Fluor 700
(clone HI30; Biolegend), CD138-BV421 (clone B-B4; Biolegend) and murine
CD45-BV510 (clone 30-F11; BD Biosciences). To measure LLP2A binding, cells
were washed and resuspended in Hanks Balanced Salt Solution (HBSS; Lonza)
containing Ca2+ (1.26 mM), Mg2+ (0.81 mM) and 0.1% bovine serum albumin
(Sigma-Aldrich). Aliquots of cells were left untreated or treated with 10 nM
BIO5192 (Tocris) at 4 °C for 15 min. Samples were then incubated with or without
LLP2A-Cy5 (0.41 µg µL−1) for 30 min at 4 °C and washed twice with HBSS.1 Dead
cells were excluded from these assays by staining with 2 mgmL−1 7-amino-
actinomycin D (Molecular Probes, Eugene, OR) for 5 min before analysis. Samples
were analysed on a Beckman Coulter Gallios ﬂow cytometer and data were ana-
lysed using FlowJo software (TreeStar, Ashland, OR). Statistical comparisons of
ﬂow cytometry data were performed using an unpaired two-tailed Student's t test
(GraphPad Prism). P values ≤0.05 were considered signiﬁcant.
Colony-forming unit assay. For enumeration of blood colony-forming cells
(CFU), aliquots of bone marrow cells were incubated in duplicate in commercially
available growth factor-supplemented methylcellulose medium for mouse CFU-C
(Stem Cell Technologies, Vancouver, BC) as described. Blood CFU were enum-
erated after 6–8 days of culture.
Competitive bone marrow transplant. C57BL/6 mice (B6.CD45.2) were treated
with either CRIT (n = 5) or PBS control (n = 5). BM was harvested on day 40 by
ﬂushing the femoral shaft with PBS. Bone marrow from treated mice was mixed
with congenic BM (B6.CD45.1/2) at a ratio of 1:1 before infusion of 1 × 106 total
BM cells into lethally irradiated (TBI 1100 cGy) B6.CD45.1 recipients via lateral tail
vein injection. Peripheral blood was analysed by ﬂow cytometry at week 8+ to
quantify engraftment of donor BM. Percentage of cells derived from treated
donor BM (CD45.2) was calculated as a percentage of total donor BM (CD45.2 +
CD45.1/2).
Statistical analysis. Statistical signiﬁcance was measured by Student’s t test using
GraphPad Prism software (GraphPad, San Diego, CA). Kaplan–Meier survival
curves were plotted using GraphPad Prism software. Unless noted otherwise, all
values are means and error bars are standard deviations. For animal studies, sample
size estimates depend on the effect size (mean difference between untreated and
treatment groups/SD) of the outcome. For effect size of 2.1 and using a two-sided t
test, typically ﬁve per group were needed with 80% power to detect a signiﬁcant
difference at a type I error rate of 0.05. There were no exclusion criteria, except for
the breast cancer study where the use of female mice was needed to recapitulate the
histopathology of female breast cancer. There was no blinding of investigators in
this research, including animal study.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author on reasonable request.
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